EFFECT - NLS Pharmaceutics Ltd. (0001783036) (Filer)
6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
F-1 - NLS Pharmaceutics Ltd. (0001783036) (Filer)
6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
ZURICH, SWITZERLAND / ACCESSWIRE / June 25, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a leading Swiss biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, announced today that it received notice from the Nasdaq Hearings Panel ("Panel") of The Nasdaq Stock Market ("Nasdaq") that it has granted the Company an extension to regain compliance with the continued listing requirements for The Nasdaq Capital Market, as discussed more fully below.Subject to the Company meeting certain financial, share price and other requirements by September 3, 2024 and October 14, 2024, the Panel granted the Compa
ZURICH, SWITZERLAND / ACCESSWIRE / June 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced the publication of the latest patent application (PCT/WO2024115797) by Aexon Labs with the World Intellectual Property Organization (WIPO). The patent will be used by NLS pursuant to its existing and previously announced license agreement with Aexon Labs."This new patent application covers groundbreaking advancements in a novel series of dual orexin receptor agonists targeting narcolepsy as the primary indication a
ZÜRICH, SWITZERLAND / ACCESSWIRE / May 28, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced promising results from its preclinical study KO-874 at the American Society of Clinical Psychopharmacology (ASCP) in Miami. This study evaluated the neuroprotective effects of mazindol on nocturnal activity in a rat model with narcoleptic-like symptoms induced by orexin-B-saporin (OX-B-SAP) lesions in the lateral hypothalamus (LH)."These data underscore our continued commitment to advancing our pipeline which has th
ZÜRICH, SWITZERLAND / ACCESSWIRE / May 24, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that on May 22, 2024, the Company received an additional staff determination letter (the "Letter") from the staff (the "Staff") of the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it did not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing set forth in Listing Rule 5550(b),
ZÜRICH, SWITZERLAND / ACCESSWIRE / April 19, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that on April 17, 2024, it received a determination letter (the "Letter") from the staff (the "Staff") of the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company of the Staff's determination that, unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the "Panel"), the Company's securities would be subject to
ZÜRICH, SWITZERLAND / ACCESSWIRE / March 22, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced the closing of its previously announced registered direct offering of 7,000,000 of its common shares at a purchase price of $0.25 per share. NLS also issued in a private placement unregistered warrants to purchase up to an aggregate of 3,500,000 common shares at an exercise price of $0.25 per share. The warrants are immediately exercisable and will expire five years fro
ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 7,000,000 of its common shares (or common share equivalents in lieu thereof) at a purchase price of $0.25 per share (or per common share equivalent in lieu thereof) in a registered direct offering. NLS has also agreed to issue in a private placement unregistered warrants to purc
The exclusive License Agreement grants NLS Pharmaceutics global rights to next-generation non-sulfonamide orexin-1 / orexin-2 receptor agonists, tailored to target multiple pathways in neuropharmacological therapies.Medications activating dual OX1R/OX2R target a broader range of mechanisms involved in neurologic disorders including narcolepsy and other hypersomnolence disordersAdditional targets covered by the exclusive License Agreement include cathepsins, sigma receptors and catecholaminergic inhibition, addressing neuroprotection, neuroinflammation and neurotransmission.First patent application was filed at the end of 2022 for orexin receptors agonists for treating or preventing neurologi
ZURICH, SWITZERLAND / ACCESSWIRE / March 14, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics will attend the BIO-EUROPE Springtime Partnering Event, bringing together over 3,700 attendees from 2,000+ companies to engage in 20,000 one-to-one meetings in Barcelona, Spain, taking place March 18-20, 2024.Please send last minute meeting requests to im@nls-pharma.comFor more information on the conference,
ZURICH, SWITZERLAND / ACCESSWIRE / March 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it has been notified by the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company's plan to regain compliance submitted on February 23, 2024 has been approved.On January 9, 2024, NLS received a letter from the Listing Qualifications staff of Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was no longer in comp
Brookline Capital initiated coverage of NLS Pharmaceutics with a rating of Buy and set a new price target of $12.00
Maxim Group initiated coverage of NLS Pharmaceutics with a rating of Buy and set a new price target of $8.00
Maxim Group initiated coverage of NLS Pharmaceutics with a rating of Buy and set a new price target of $8.00
Maxim Group initiated coverage of NLS Pharmaceutics with a rating of Buy
Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday's session following third-quarter results. Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, beating the analyst consensus estimate of $6.53 billion. The print manufacturing company's adjusted EPS of $1.89 beat the analyst consensus of $1.85, according to data from Benzinga Pro. Jabil said it expects fourth-quarter revenue of $6.3 billion – $6.9 billion (consensus: $6.8 billion) and adjusted EPS to $2.03 – $2.43 (consensus: $2.22). Jabil shares dipped 7.8% to $116.37 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers MGO Global, Inc. (NA
U.S. stocks traded mixed this morning, with the S&P 500 gaining around 0.1% on Thursday. Following the market opening Thursday, the Dow traded down 0.10% to 38,795.35 while the NASDAQ rose 0.16% to 17,890.82. The S&P 500 also rose, gaining, 0.12% to 5,493.76. Check This Out: Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday Leading and Lagging SectorsFinancial shares jumped by 0.6% on Thursday. In trading on Thursday, communication services shares fell by 0.8%. Top Headline The U.S. current account deficit rose by $15.8 billion to $237.6 billion during the first quarter, and versus market estimates of a $206.4 billion gap. Equities Trading UP
Shares of Vuzix Corporation (NASDAQ:VUZI) rose sharply in today's pre-market trading after the company disclosed a strategic partnership with Avegant to develop optimized waveguide optical modules for use in future AI-enabled smart glasses. Vuzix shares jumped 15% to $1.53 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers SMX (Security Matters) Public Limited Company (NASDAQ:SMX) rose 109.8% to $0.2497 in pre-market trading after jumping 19% on Tuesday. Selina Hospitality PLC (NASDAQ:SLNA) gained 46.9% to $0.1024 in pre-market trading after declining 7% on Tuesday. Tempest Therapeutics, Inc. (NASDAQ:TPST) shares rose 44.5%
Shares of Quantum Corporation (NASDAQ:QMCO) fell sharply during Tuesday's session after the company reported worse-than-expected FY24 financial results and issued FY25 guidance below estimates. Quantum shares dipped 44.5% to $0.43 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Reliance Global Group, Inc. (NASDAQ:RELI) shares jumped 350% to $1.00 after the company issued an update on the pending acquisition of Spetner Associates. NLS Pharmaceutics AG (NASDAQ:NLSP) shares rose 166% to $0.3930 after jumping 30% on Monday. Actelis Networks, Inc. (NASDAQ:ASNS) climbed 80.9% to $2.08 after the company announced a partnership with Carahsoft Tech
U.S. stocks traded mixed this morning, with the Nasdaq Composite edging lower on Tuesday. Following the market opening Tuesday, the Dow traded up 0.25% to 38,875.50 while the NASDAQ fell 0.12% to 17,836.13. The S&P 500 also rose, gaining, 0.15% to 5,481.48. Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 8% Dividend Yields Leading and Lagging SectorsEnergy shares jumped by 1.6% on Tuesday. In trading on Tuesday, consumer discretionary shares fell by 0.4%. Top Headline U.S. retail sales rose 0.1% month-over-month in May compared to a revised 0.2% declined in April and missing market expectations of 0.2% gain. Equities Tradi
Shares of Chegg, Inc. (NYSE:CHGG) rose sharply in today's pre-market trading after the company announced a restructuring plan and new vision for growth. The restructuring plan will include a 23% headcount reduction, a refocus on students with a comprehensive course load and dedication of more resources to its international program. Chegg shares jumped 20.7% to $3.15 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Actelis Networks, Inc. (NASDAQ:ASNS) rose 112.2% to $2.44 in pre-market trading after the company announced a partnership with Carahsoft Technology Corp. NLS Pharmaceutics AG (NASDAQ:NLSP) shares rose 62.8% to $0
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced the publication of the latest patent application (PCT/WO2024115797) by Aexon Labs with the World Intellectual Property Organization (WIPO). The patent will be used by NLS pursuant to its existing and previously announced license agreement with Aexon Labs.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced promising results from its preclinical study KO-874 at the American Society of Clinical Psychopharmacology (ASCP) in Miami. This study evaluated the neuroprotective effects of mazindol on nocturnal activity in a rat model with narcoleptic-like symptoms induced by orexin-B-saporin (OX-B-SAP) lesions in the lateral hypothalamus (LH).
Professor Claudio L. A. Bassetti, MD, is the Chair, Neurology Department, Inselspital, Bern University Hospital and Dean, Medical Faculty, University of Bern, focused on sleep disordersProfessor Florence Allouche Aknin, PharmD, MBA, is a professor at University Paris City, specializing in pharmaceutical innovation, entrepreneurship and fundraisingZURICH, SWITZERLAND / ACCESSWIRE / November 28, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW))) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that, subject to final ap
ZURICH, SWITZERLAND / ACCESSWIRE / August 28, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW))) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders:NLS Pharmaceutics CEO Issues Letter to ShareholdersTo our Shareholders and Friends,Though we may have been quiet recently, I wanted to assure you that the team here at NLS has been very busy behind the scenes ensuring that we realize our vision of awakening a brighter future for pa
ZÜRICH, SWITZERLAND / ACCESSWIRE / May 8, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that Keith Harrison Dewedoff has been appointed to the position of Interim Chief Financial Officer ("CFO"). A versatile strategic leader within healthcare, Mr. Dewedoff brings more than 20 years of experience in the life sciences industry, ranging from biotech venture-backed start-ups to commercial publicly traded companies. Mr. Dewedoff also serves as a CFO and Advisor fo
Company also announces expected departure of Sylvia Panigone, Ph.D.ZURICH, SWITZERLAND / ACCESSWIRE / September 8, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW))) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Dr. George Apostol has been appointed to the position of Chief Medical Officer and Global Head of Research and Development ("R&D"). Serving most recently as Global Head of Research and Development at Endo Pharmaceuticals Inc. ("Endo"), Dr. Apostol brings significant expertise in the management and execution
ZURICH, SWITZERLAND / ACCESSWIRE / June 6, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Chad C. Hellmann has been appointed to the position of Chief Financial Officer ("CFO"). Serving most recently as CFO and co-portfolio manager of Arcus Ventures, Mr. Hellmann brings to NLS significant expertise in developing and implementing operational strategies and capital markets solutions for life sciences companies. NLS also announces that Subhasis Roy has resigned a
STANS, SWITZERLAND / ACCESSWIRE / July 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system (CNS) disorders, announces the appointment of Eric Konofal, M.D., Ph.D., as Chief Scientific Officer. Dr. Konofal is a co-founder and has over 30 years of experience as a physician and leading researcher in the field of sleep disorders and other CNS diseases."As a co-founder of NLS, Eric has already made enormous contributions to the Company with regard to our early work on Quilience® and Nolazol®, and now he is able to fully
STANS, Switzerland, April 5, 2021 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces the appointment of Silvia Panigone, Ph.D., eMBA as Chief Operating Officer. Dr. Panigone brings to NLS over 25 years of leadership experience in the healthcare industry, founding and operating ADYA Consulting, a boutique advisory firm that provides strategic counseling, access to capital, and M&A advisory services to companies in the life sciences sector, and serving in operational and
SC 13G - NLS Pharmaceutics Ltd. (0001783036) (Subject)
SC 13G/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)
SC 13G - NLS Pharmaceutics Ltd. (0001783036) (Subject)
SC 13G/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)
SC 13G/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)
SC 13G/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)
SC 13G - NLS Pharmaceutics Ltd. (0001783036) (Subject)
SC 13G - NLS Pharmaceutics Ltd. (0001783036) (Subject)
SC 13G - NLS Pharmaceutics Ltd. (0001783036) (Subject)
SC 13G - NLS Pharmaceutics Ltd. (0001783036) (Subject)
EFFECT - NLS Pharmaceutics Ltd. (0001783036) (Filer)
6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
ZURICH, SWITZERLAND / ACCESSWIRE / June 25, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a leading Swiss biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, announced today that it received notice from the Nasdaq Hearings Panel ("Panel") of The Nasdaq Stock Market ("Nasdaq") that it has granted the Company an extension to regain compliance with the continued listing requirements for The Nasdaq Capital Market, as discussed more fully below.Subject to the Company meeting certain financial, share price and other requirements by September 3, 2024 and October 14, 2024, the Panel granted the Compa
Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday's session following third-quarter results. Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, beating the analyst consensus estimate of $6.53 billion. The print manufacturing company's adjusted EPS of $1.89 beat the analyst consensus of $1.85, according to data from Benzinga Pro. Jabil said it expects fourth-quarter revenue of $6.3 billion – $6.9 billion (consensus: $6.8 billion) and adjusted EPS to $2.03 – $2.43 (consensus: $2.22). Jabil shares dipped 7.8% to $116.37 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers MGO Global, Inc. (NA
U.S. stocks traded mixed this morning, with the S&P 500 gaining around 0.1% on Thursday. Following the market opening Thursday, the Dow traded down 0.10% to 38,795.35 while the NASDAQ rose 0.16% to 17,890.82. The S&P 500 also rose, gaining, 0.12% to 5,493.76. Check This Out: Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday Leading and Lagging SectorsFinancial shares jumped by 0.6% on Thursday. In trading on Thursday, communication services shares fell by 0.8%. Top Headline The U.S. current account deficit rose by $15.8 billion to $237.6 billion during the first quarter, and versus market estimates of a $206.4 billion gap. Equities Trading UP
Shares of Vuzix Corporation (NASDAQ:VUZI) rose sharply in today's pre-market trading after the company disclosed a strategic partnership with Avegant to develop optimized waveguide optical modules for use in future AI-enabled smart glasses. Vuzix shares jumped 15% to $1.53 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers SMX (Security Matters) Public Limited Company (NASDAQ:SMX) rose 109.8% to $0.2497 in pre-market trading after jumping 19% on Tuesday. Selina Hospitality PLC (NASDAQ:SLNA) gained 46.9% to $0.1024 in pre-market trading after declining 7% on Tuesday. Tempest Therapeutics, Inc. (NASDAQ:TPST) shares rose 44.5%
Shares of Quantum Corporation (NASDAQ:QMCO) fell sharply during Tuesday's session after the company reported worse-than-expected FY24 financial results and issued FY25 guidance below estimates. Quantum shares dipped 44.5% to $0.43 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Reliance Global Group, Inc. (NASDAQ:RELI) shares jumped 350% to $1.00 after the company issued an update on the pending acquisition of Spetner Associates. NLS Pharmaceutics AG (NASDAQ:NLSP) shares rose 166% to $0.3930 after jumping 30% on Monday. Actelis Networks, Inc. (NASDAQ:ASNS) climbed 80.9% to $2.08 after the company announced a partnership with Carahsoft Tech
U.S. stocks traded mixed this morning, with the Nasdaq Composite edging lower on Tuesday. Following the market opening Tuesday, the Dow traded up 0.25% to 38,875.50 while the NASDAQ fell 0.12% to 17,836.13. The S&P 500 also rose, gaining, 0.15% to 5,481.48. Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 8% Dividend Yields Leading and Lagging SectorsEnergy shares jumped by 1.6% on Tuesday. In trading on Tuesday, consumer discretionary shares fell by 0.4%. Top Headline U.S. retail sales rose 0.1% month-over-month in May compared to a revised 0.2% declined in April and missing market expectations of 0.2% gain. Equities Tradi
Shares of Chegg, Inc. (NYSE:CHGG) rose sharply in today's pre-market trading after the company announced a restructuring plan and new vision for growth. The restructuring plan will include a 23% headcount reduction, a refocus on students with a comprehensive course load and dedication of more resources to its international program. Chegg shares jumped 20.7% to $3.15 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Actelis Networks, Inc. (NASDAQ:ASNS) rose 112.2% to $2.44 in pre-market trading after the company announced a partnership with Carahsoft Technology Corp. NLS Pharmaceutics AG (NASDAQ:NLSP) shares rose 62.8% to $0